Boai NKY Medical News

Some Investors May Be Willing To Look Past Boai NKY Medical Holdings' (SZSE:300109) Soft Earnings

Simply Wall StApr 29 19:05 ET

These 4 Measures Indicate That Boai NKY Medical Holdings (SZSE:300109) Is Using Debt Reasonably Well

Simply Wall StApr 22 20:47 ET

Boai NKY Medical: Last year's Net income decreased by about 30% year-on-year, the proportion of Medical Services Business fell below 10% | Interpretations

① The gross margin of the PVP series products is under pressure, and the company's revenue will increase while profits decrease in 2024; ② The Medical Services business now accounts for less than 10% of the company's performance.

cls.cnApr 18 20:26 ET

NEW OPEN SOURCE: 2025 FIRST QUARTER REPORT

SZSIApr 18 12:00 ET · Announcements

New Open Source: 2024 Annual Report Summary

SZSIApr 18 12:00 ET · Announcements

NEW OPEN SOURCE: 2024 ANNUAL REPORT

SZSIApr 18 12:00 ET · Announcements

Boai NKY Medical (300109.SZ): In the first quarter, the Net income was 80.4203 million yuan, a year-on-year decrease of 33.75%.

On April 18, Gelonghui reported that Boai NKY Medical (300109.SZ) announced its first-quarter report for 2025, achieving a revenue of 0.325 billion yuan in the first quarter, a year-on-year decrease of 17.69%; the Net income attributable to the shareholders of the listed company was 80.4203 million yuan, a year-on-year decrease of 33.75%; the Net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 69.4162 million yuan, a year-on-year decrease of 44.85%; and the EPS was 0.17 yuan.

Gelonghui FinanceApr 18 06:04 ET

Boai NKY Medical (300109.SZ): Sales in the USA account for approximately 3-5% of the company's total sales.

Gelonghui reported on April 9 that Boai NKY Medical (300109.SZ) stated on the investor interaction platform that sales in the USA account for approximately 3-5% of the company's total sales.

Gelonghui FinanceApr 9 03:27 ET

Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.

In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.

cls.cnApr 6 20:17 ET

Boai NKY Medical (300109.SZ): Products can be used in Solid State Battery.

On April 1, Gelonghui announced that Boai NKY Medical (300109.SZ) stated on the investor interaction platform that the company's products can be used in Solid State Batteries.

Gelonghui FinanceApr 1 04:13 ET

Fewer Investors Than Expected Jumping On Boai NKY Medical Holdings Ltd. (SZSE:300109)

Simply Wall StMar 25 22:23 ET

GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong FinanceMar 16 21:18 ET

Boai NKY Medical (300109.SZ): The PVP shipment volume in 2024 is more than 0.02 million tons.

On March 14, Gelonghui reported that Boai NKY Medical (300109.SZ) stated on the investor interaction platform that the company's PVP shipment volume for 2024 is over 0.02 million tons, with more than 3,000 tons shipped in the New energy Fund. The company is planning to establish new production capacity projects to enhance supply capabilities in the future.

Gelonghui FinanceMar 14 04:50 ET

The Guangzhou computing power center has connected to the Alibaba Tongyi Qianwen large model.

Xinhuanet Technology reported on the afternoon of March 11 that Sina Technology learned that the Guangzhou AI public computing power center has successfully adapted and launched the latest open-source QwQ-32B inference model by Tongyi Qianwen. It is understood that the QwQ-32B is the latest open-source inference model from the Alibaba Tongyi team, which performs comparably to the 'full-version' 671B DeepSeek-R1 in multiple authoritative evaluations of mathematics, coding, and general capabilities, far outperforming the o1-mini and the R1 distilled model of the same size.

Sina TechnologyMar 11 04:03 ET

Boai NKY Medical (300109.SZ): Our company has maintained approximately a 50% growth rate in 2024, and it is expected that shipments will be around 2,000 tons this year.

Gelonghui reported on March 6 that Boai NKY Medical (300109.SZ) recently stated during an investor relations event that the company will maintain an increase of about 50% for its Eurorise products in 2024, with a shipment volume of over 1,500 tons, a high price, and a gross margin of 60-70%. It is expected to ship about 2,000 tons this year.

Gelonghui FinanceMar 6 02:05 ET

Boai NKY Medical (300109.SZ): The company is engaged in the development of tumor screening business that combines AI morphological auxiliary diagnosis.

Gelonghui, March 5th丨Boai NKY Medical (300109.SZ) stated on the investor interaction platform that the company's tumor screening Business involves research and development in AI morphological assisted diagnosis.

Gelonghui FinanceMar 5 09:27 ET

Earnings Growth Outpaced the Favorable 15% CAGR Delivered to Boai NKY Medical Holdings (SZSE:300109) Shareholders Over the Last Three Years

Simply Wall StMar 4 02:44 ET

Alibaba Earnings Reports: AI drives cloud Business back to double-digit growth with over 0.09 million derivative models.

On February 20, Alibaba Group announced its third-quarter results for the fiscal year 2025 (natural year October-December 2024), showing an accelerated growth trend in Alibaba's core Business under the "AI-driven" Global Strategy. In this quarter, Alibaba Cloud's AI-related product revenue achieved triple-digit year-on-year growth for six consecutive quarters, helping Alibaba Cloud's revenue return to double-digit growth at 13%. The AI-driven marketing tool "Full Site Promotion" saw a steady increase in merchant penetration. Recently, Alibaba's brand new open-source flagship model Qwen2.5-Max gained significant attention, achieving globally leading results in multiple authoritative benchmark tests.

Global Market ReportFeb 20 08:06 ET

Alibaba's Q3 Earnings Reports: Cloud and e-commerce accelerated growth, with AI revenue showing triple-digit growth for six consecutive quarters.

On February 20, Alibaba Group released the performance for the third quarter of fiscal year 2025, highlighting that the focus on Global Strategy over the past year has yielded continuous results, with core Business accelerating growth. In this quarter, e-commerce Business grew rapidly, Alibaba Cloud's commercial revenue returned to double-digit growth, and revenue from AI-related products maintained triple-digit growth for six consecutive quarters. Standing at the starting point of a new technological cycle, AI is expected to become Alibaba's new growth engine for the future. 'This quarter's performance fully demonstrates our significant progress in the strategy of 'User First, AI Driven', with core Business growth accelerating once again. In this quarter, the customer management revenue of Taotian Group grew by 9%, with

Global market report.Feb 20 05:41 ET

Boai NKY Medical (300109.SZ): It is expected that this year there will still be a certain increase in Order and shipment volume in the New energy Fund.

On February 17, Gelonghui reported that Boai NKY Medical (300109.SZ) stated on the investor interaction platform that the company expects a certain increase in orders and shipments in the New energy Fund this year.

Gelonghui FinanceFeb 17 03:35 ET